Propanc Health Group Corp (OTCMKTS:PPCH) has announced the signing of Maxim Group LLC, as the strategic advisor to the company. The company is known for its services in the investment banking and management industry. Propanc has remained unimpressive in 2014, but has shown a lot of promise recently, assisted by the NY times Health Essentials article: “Cancer Prevention and Treatment”.
The company’s main focus of the company is development of treatments for colorectal and pancreatic cancer. The current formulations from the company are known to control and prevent tumors from spreading throughout the body. The PPCH formulations are all variations of a formulation that employs pro-enzymes for the treatment. The company hopes to push its products into clinical and non-clinical trials to get the FDA approval.
For now PPCH plans to put patients with limited treatment options, through the trial. PPCH, on May 5 had announced the results of it animal trials, reporting no adverse effects of the drug. However, there has not been a significant change in terms of shareholder value of the company. This is the reason that PPCH has requested for the services of Maxim. The company hopes that the investment banking company can help it increase its shareholder value to significant levels.
The current course of actions, advised by Maxim, is to get the PPCH stock listed on a national exchange. The CEO of PPCH, James Nathanieslz, stated that his company is delighted to gain the services of Maxim. The company hopes that the move will quicken the implementation of their strategic plans.
Maxim has also agreed to enter into the agreement after seeing the potential that PPCH holds. The investment bank sees a strong IP portfolio, growth prospects, a large market and a great management team in PPCH. Maxim plans to advise the company on strategic developments and potential acquisitions that might make it stronger financially.
Propanc Health Group Corp (OTCMKTS:PPCH) closed at $0.0445, after losing 20.54% on May 14. The company has 191.69 million shares being traded in the company, with a 52-week range of $0.00-$0.47.
